Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 7/20 | 0.48 |
| ▸ | CTSB | P07858 | 6/20 | 0.48 |
| ▸ | CTSV | O60911 | 6/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451686 | 1.00 | FPR2 (0.49) | FPR2CTSLCTSBCTSVCTSS | |
| SCHEMBL12678088 | 0.84 | MME (0.59) | FPR2 | |
| SCHEMBL27477804 | 0.83 | CTSL (0.53) | FPR2CTSLCTSBCTSVCTSS | |
| SCHEMBL29981912 | 0.83 | FOLH1 (0.52) | FPR2CTSLCTSBCTSVCTSS | |
| SCHEMBL27552211 | 0.83 | CTSL (0.53) | FPR2CTSLCTSBCTSVCTSS | |
| SCHEMBL4308790 | 0.82 | CA2 (0.56) | FPR2GPR34PYGLKMT2A | |
| SCHEMBL25045736 | 0.82 | CTSL (0.52) | FPR2CTSLCTSBCTSVCTSS | |
| SCHEMBL23279689 | 0.81 | CTSV (0.70) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL20591555 | 0.81 | CTSV (0.70) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL23279600 | 0.81 | CTSL (0.70) | CTSLCTSBCTSVCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| CN-1946703-A | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators | TRANSTECH PHARMA INC (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1753735-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | Transtech Pharma, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | disclosed |
| WO-2005103022-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | TRANSTECH PHARMA, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | FPR2 279/4885CTSL 3816/4885CTSB 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.